Intas Pharmaceuticals is the largest privately held pharmaceutical company in India, with a focus on value-added products such as biosimilars, improved generics using novel drug delivery systems, and innovative active pharmaceutical ingredients. The company has an extensive geographic footprint, with over 80% of export revenue coming from the US, UK, and EU. Intas operates over 10 manufacturing facilities worldwide, with regulatory approvals from multiple global agencies, and employs over 12,000 people globally, with over 800 scientists and 400 located in Europe. The company invests approximately 6-7% of its revenues in R&D and has over 10,000 product registrations worldwide. Intas is known for its leadership in key therapeutic segments such as CNS, Cardio, Diabeto, Gastro, Urology, and Oncology in India, and has established a highly advanced EU-GMP Certified Biopharma division to provide affordable biosimilars across niche segments.